According to @godofprompt on X, a viral claim cites that $3,000 in DNA sequencing plus a ChatGPT subscription and free AlphaFold enabled a personalized mRNA cancer vaccine design that reportedly shrank a tumor by 50%, with the original story reported by The Australian about a tech executive who used AI tools to create a vaccine for his dog. According to The Australian, the workflow combined next-generation sequencing, protein structure prediction via AlphaFold, and LLM-guided analysis and design, dramatically compressing cost and time compared with traditional academic pipelines. As reported by The Australian, the case underscores emerging business opportunities for AI-driven precision oncology tooling—such as turnkey neoantigen discovery, LLM-assisted peptide ranking, and GMP-ready vaccine design—but it also raises regulatory, clinical validation, and safety concerns requiring oversight and reproducibility. According to The Australian, the practical takeaway for industry is the rising demand for end-to-end platforms that integrate sequencing, neoantigen calling, structure prediction, immunogenicity scoring, and manufacturability checks with audit trails, which could enable clinics and biotech startups to operationalize patient-specific vaccines faster while maintaining compliance.